Gulf International Bank UK Ltd increased its stake in shares of Zimmer Biomet Holdings Inc. (NYSE:ZBH) by 6.3% during the third quarter, according to its most recent disclosure with the SEC. The firm owned 61,383 shares of the company’s stock after buying an additional 3,650 shares during the period. Gulf International Bank UK Ltd’s holdings in Zimmer Biomet Holdings were worth $7,981,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in ZBH. Cohen & Steers Inc. boosted its stake in shares of Zimmer Biomet Holdings by 2,057.7% in the second quarter. Cohen & Steers Inc. now owns 2,814,345 shares of the company’s stock valued at $60,874,000 after buying an additional 2,683,915 shares during the period. Winslow Capital Management LLC acquired a new position in shares of Zimmer Biomet Holdings during the second quarter worth about $310,013,000. Ameriprise Financial Inc. boosted its position in shares of Zimmer Biomet Holdings by 38.9% in the second quarter. Ameriprise Financial Inc. now owns 4,853,226 shares of the company’s stock worth $584,179,000 after buying an additional 1,359,249 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Zimmer Biomet Holdings by 8.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 17,028,139 shares of the company’s stock worth $2,049,848,000 after buying an additional 1,340,461 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Zimmer Biomet Holdings by 12.3% in the second quarter. Vanguard Group Inc. now owns 11,940,582 shares of the company’s stock worth $1,437,408,000 after buying an additional 1,306,447 shares during the last quarter. Hedge funds and other institutional investors own 85.05% of the company’s stock.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Shares of Zimmer Biomet Holdings Inc. (NYSE:ZBH) traded up 1.162% during mid-day trading on Tuesday, hitting $103.165. 1,518,782 shares of the company’s stock were exchanged. Zimmer Biomet Holdings Inc. has a 52 week low of $88.27 and a 52 week high of $133.21. The company has a market capitalization of $20.66 billion, a price-to-earnings ratio of 57.763 and a beta of 1.28. The firm has a 50 day moving average price of $112.33 and a 200-day moving average price of $121.63.

Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings data on Monday, October 31st. The company reported $1.79 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.79. The business had revenue of $1.83 billion for the quarter, compared to the consensus estimate of $950.20 million. Zimmer Biomet Holdings had a net margin of 3.46% and a return on equity of 16.48%. Zimmer Biomet Holdings’s quarterly revenue was up 4.0% on a year-over-year basis. During the same quarter last year, the company posted $1.64 earnings per share. On average, equities analysts anticipate that Zimmer Biomet Holdings Inc. will post $7.92 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2016/11/29/zimmer-biomet-holdings-inc-zbh-position-raised-by-gulf-international-bank-uk-ltd.html.

ZBH has been the subject of a number of research reports. Royal Bank Of Canada cut their target price on shares of Zimmer Biomet Holdings from $143.00 to $130.00 and set an “outperform” rating for the company in a research report on Tuesday, November 1st. Northcoast Research cut shares of Zimmer Biomet Holdings from a “buy” rating to a “neutral” rating in a research report on Tuesday, November 8th. RBC Capital Markets set a $143.00 target price on shares of Zimmer Biomet Holdings and gave the stock a “buy” rating in a research report on Wednesday, September 14th. Barclays PLC lifted their target price on shares of Zimmer Biomet Holdings from $140.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 23rd. Finally, Argus restated a “buy” rating and set a $140.00 target price on shares of Zimmer Biomet Holdings in a research report on Thursday, September 22nd. Four analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the stock. Zimmer Biomet Holdings currently has an average rating of “Buy” and a consensus price target of $131.15.

In other news, insider Daniel E. Williamson sold 2,716 shares of the firm’s stock in a transaction on Thursday, September 8th. The shares were sold at an average price of $129.96, for a total value of $352,971.36. Following the sale, the insider now owns 2,000 shares in the company, valued at $259,920. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 1.22% of the stock is currently owned by insiders.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

5 Day Chart for NYSE:ZBH

Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.